{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.0"},{"groupId":"OG001","spread":"12.2","value":"31.6"},{"groupId":"OG002","spread":"9.5","value":"33.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.1","value":"32.0"},{"groupId":"OG001","spread":"12.2","value":"40.2"},{"groupId":"OG002","spread":"8.5","value":"56.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Prior to Maintenance Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.4","value":"39.0"},{"groupId":"OG001","spread":"12.3","value":"39.8"},{"groupId":"OG002","spread":"26.2","value":"18.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Completion of Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.7","value":"42.3"},{"groupId":"OG001","spread":"14.5","value":"41.0"},{"groupId":"OG002","value":"33.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"12 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.0","value":"43.4"},{"groupId":"OG001","spread":"13.4","value":"40.1"},{"groupId":"OG002","spread":"8.9","value":"32.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"24 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.8","value":"51.2"},{"groupId":"OG001","spread":"13.6","value":"41.0"},{"groupId":"OG002","spread":"18.7","value":"48.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"36 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.9","value":"48.6"},{"groupId":"OG001","spread":"11.3","value":"46.1"},{"groupId":"OG002","spread":"8.3","value":"42.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"48 Months Off Therapy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.8","value":"43.1"},{"groupId":"OG001","spread":"13.3","value":"42.3"},{"groupId":"OG002","spread":"12.7","value":"36.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"60 Months Off Therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"Scores measuring visual-spatial reasoning were obtained from Visual Perception T-scores on the Beery Visual Motor Integration (VMI) instrument. Higher scores indicate better performance. The normative mean is 50 with a standard deviation of 10.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"MEAN","populationDescription":"Eligible patients with scores at any of the data collection timepoints were included. Sample sizes differ across timepoints as not all subjects had scores for all timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, prior to maintenance therapy, completion of therapy, and 12 months, 24 months, 36 months, 48 months, and 60 months off therapy","title":"Neurocognitive Performance Related to Visual-spatial Reasoning as Measured by Visual Perception T-scores","type":"SECONDARY","unitOfMeasure":"score on a scale"}